Devarajan Prasad, Murray Patrick
Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Nephron Clin Pract. 2014;127(1-4):176-9. doi: 10.1159/000363206. Epub 2014 Sep 24.
Novel biomarkers are required to improve the timely detection of early acute kidney injury (AKI) and to improve the differential diagnosis, prognostic assessment, and management of AKI cases. It is anticipated that novel biomarkers of early structural AKI ('acute kidney damage') will provide critical diagnostic and prognostic stratification and complement functional markers such as serum creatinine. Further studies are required to conclusively demonstrate the association between early kidney damage biomarkers and clinical outcomes, both with and independently of functional markers, and to discern whether or not randomization to a treatment for AKI based on high structural/damage biomarker levels results in an improvement in kidney function and clinical outcomes.
需要新型生物标志物来改善早期急性肾损伤(AKI)的及时检测,并改善AKI病例的鉴别诊断、预后评估和管理。预计早期结构性AKI(“急性肾损伤”)的新型生物标志物将提供关键的诊断和预后分层,并补充诸如血清肌酐等功能标志物。需要进一步研究来确凿地证明早期肾损伤生物标志物与临床结局之间的关联,无论是否依赖于功能标志物,并确定基于高结构性/损伤生物标志物水平随机接受AKI治疗是否能改善肾功能和临床结局。